Table 3.
Falciparum cases treated with intravenous artesunate from the Hospital for Tropical Diseases (HTD)
| Age | Gender | County of residence | Country of travel | Parasitaemia on admission | Number of clinical features of severity | Admitting hospital | Site of first artesunate dose | Diagnosis-to-treatment time (h) | Initial antimalarial |
|---|---|---|---|---|---|---|---|---|---|
| 57 | M | UK | Nigeria | 2.3 | 1 | Elsewhere | Elsewhere | 12 | IV quinine and doxycycline |
| 41 | M | UK | Gambia | 15 | 6 | Elsewhere | Elsewhere | 13 | IV quinine |
| 34 | F | UK | Nigeria | 37 | 1 | Elsewhere | HTD | 14 | IV quinine |
| 45 | M | UK | Gambia and Liberia | 27 | 0 | Elsewhere | HTD | 41.5 | IV quinine |
| 51 | M | UK | Nigeria | 15 | 3 | Elsewhere | HTD | 13 | IV quinine |
| 62 | F | UK | Ghana | 17 | 0 | Elsewhere | Elsewhere | 5 | IV quinine |
| 38 | M | UK | Nigeria | 8 | 1 | Elsewhere | Elsewhere | 26 | IV quinine and im artemether |
| 24 | F | UK | Uganda | 2.7 | 0 | HTD | HTD | 1 | IV artesunate |
| 24 | M | UK | Thailand | 2.6 | 0 | Elsewhere | HTD | 29 | IV quinine |
| 39 | M | UK | Kenya | 23 | 3 | Elsewhere | Elsewhere | 4.5 | IV quinine |
| 46 | M | UK | Nigeria | 8.1 | 2 | Elsewhere | HTD | 34 | IV quinine |
| 41 | M | UK | Uganda | 2.3 | 2 | Elsewhere | HTD | 9 | IV quinine |
| 47 | F | UK | Mozambique | 0.2 (recurrence) | 0 | HTD | HTD | 5 | IV artesunate |
| 46 | M | UK | Sudan | 20 | 2 | Elsewhere | Elsewhere | 8 | IV quinine |
| 45 | F | UK | Uganda | 1.8 | 1 | Elsewhere | HTD | 45 | IV quinine |
| 42 | M | UK | Nigeria | 1 | 0 | HTD | HTD | 3.5 | IV artesunate |
| 36 | M | UK | Nigeria | 0.3 | 1 | HTD | HTD | 1 | IV artesunate |
| 49 | M | UK | DR Congo | 15 | 1 | HTD | HTD | 5 | IV quinine |
| 17 | M | UK | Sierra Leone | 1.1 | 0 | HTD | HTD | 11 | IV quinine |
| 52 | F | UK | Ghana | 50 | 4 | Elsewhere | Elsewhere | Unknown | IV quinine |
| 34 | F | UK | Ghana | 22 | 4 | Elsewhere | Elsewhere | 4 | IV artesunate and clindamycin |
| 52 | F | UK | Sierra Leone | 5.2 | 0 | Elsewhere | Elsewhere | Unknown | Unknown |
| 27 | F | UK | Tanzania | 5 | 0 | Elsewhere | HTD | Unknown | IV quinine |
| 52 | M | UK | Kenya | 10 | 1 | Elsewhere | HTD | 33 | IV quinine |
| 36 | M | UK | Gabon | 17.2 | 0 | HTD | HTD | 0.5 | IV artesunate |
| 41 | F | UK | Ghana | 10 | 1 | Elsewhere | Elsewhere | 7.5 | IV quinine and doxycycline |
| 35 | F | UK | Ghana and Ivory Coast | 9 | 0 | Elsewhere | Elsewhere | Unknown | IV quinine |
| 70 | M | UK | Nigeria | 8 | 1 | Elsewhere | Elsewhere | Unknown | IV quinine |
| 51 | M | UK | Nigeria | 9.2 | 0 | Elsewhere | Elsewhere | 5 | IV quinine |
| 39 | M | UK | Uganda | 30 | 2 | Elsewhere | HTD | Unknown | IV quinine |
| 31 | F | UK | Nigeria | 4.8 | 1 | Elsewhere | HTD | Unknown | IV quinine |
| 30 | M | UK | Sierra Leone | 26.8 | 2 | Elsewhere | HTD | 21.5 | IV quinine |
| 47 | F | UK | Sierra Leone | 12.5 | 2 | Elsewhere | HTD | 14.5 | IV quinine |
| 43 | M | UK | Ghana | 16.4 | 3 | Elsewhere | HTD | Unknown | IV quinine |
F, female; IV, intravenous; M, male.